CareDx Inc ( (CDNA) ) has released its Q2 earnings. Here is a breakdown of the information CareDx Inc presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CareDx, Inc., headquartered in Brisbane, California, is a precision medicine company specializing in genomics-based solutions for transplant patients and caregivers, offering testing services, products, and digital healthcare solutions throughout the transplant journey.
In its second quarter of 2025, CareDx reported significant growth in testing services volume, with a 13% year-over-year increase, and narrowed its full-year revenue guidance to between $367 million and $373 million. The company also highlighted the launch of its AI-driven diagnostic platform, AlloSure Plus, and its strong presence at the 2025 World Transplant Congress.
Financially, CareDx achieved an adjusted revenue of $90.5 million, marking a 14% increase from the previous year, despite a GAAP net loss of $8.6 million. The adjusted testing services revenue also rose by 14% to $65.9 million. The company reported a non-GAAP net income of $5.6 million, although this was a decrease from the $13.6 million reported in the same quarter of 2024.
Looking ahead, CareDx remains optimistic about its financial performance, with a narrowed revenue guidance for 2025 and expectations of continued growth in adjusted EBITDA. The company is committed to enhancing its market leadership in transplant care through innovative solutions and strategic initiatives.